Narrative data is a valuable asset in healthcare but is largely inaccessible due to its lack of structure as existing technologies rely on structured data or key word searches. CLiX can ‘read’ thousands of clinical documents an hour and extract the information they contain. This has significant benefit, as shown with the Rady collaboration, in the clinical setting and is also very powerful for clinical trials as it can optimize the development process along the entire continuum – site selection, protocol optimization and enrolment. In simple terms our software can automate the bulk of pre-screening and site feasibility which is still undertaken manually. By targeting very specific patient inclusion/exclusion criteria, even down to specific start and stop events, varying dose levels and thousands of other variable criteria software can be used to speed up clinical trials.

Sarah Beeby, continued: “As well as being an incredibly empowering project to be involved with it also enabled us to put CLiX through its paces and be even more confident in its ability. By using CLiX in the clinical trial setting we can offer significant de-risking for the program and potentially significant savings in development time by decreasing the total enrolment time, reducing protocol amendments, improving data robustness for the next development stage. As we all know time is a big factor with a significant number of trials failing to meet enrolment timelines.”


Clinithink CEO, Chris Tackaberry said: “Sarah has huge experience in the life science industry and we are really excited that she has chosen to join Clinithink as the executive leading our life science business. We are confident we can make a real difference in this space and have already seen exciting traction since Sarah has joined us.”

Back to HCB News

More People on the Move